May 2, 2014 | Letter
Excerpt: One goal of the incentive auction legislation was to bring market forces, via auctions, to bear on the question of how best to allocate spectrum resources. A pure market-based approach would allow all qualified bidders to freely bid on spectrum licenses, thereby determining whether broadcasting or commercial wireless is the highest economic use of the spectrum.
May 1, 2014 | Letter
Excerpt: Thank you for your cooperation with the committee’s March 13 request on enrollment data. Due to the administration’s repeated delays and extensions, we believe additional data is required to determine who has enrolled and paid for a plan on the Federally-Facilitated Marketplace.
April 22, 2014 | Letter
Excerpt: The process followed by FDA in proposing this rule appears to stand in stark contrast to the approach taken by the agency in developing changes to the content and format of prescription drug labeling under the Clinton administration.
April 18, 2014 | Letter
Excerpt: The IG Management Alert raises questions concerning FERC’s management and controls of sensitive information pertaining to the integrity and security of electric grid and other critical infrastructure. In light of this report and our ongoing oversight, we write pursuant to Rules X and XI of the U.S.
April 17, 2014 | Letter
Excerpt: Since the enactment of the Farm Bill, the way in which some states are misusing LIHEAP payments since the enactment of the Farm Bill may prevent families who are eligible for LIHEAP from receiving this assistance. The Congressional Research Service reports that LIHEAP funding is not sufficient to assist every household that is eligible for the program.
April 3, 2014 | Letter
Excerpt: On February 26, 2014, CMS Principal Deputy Administrator Jonathan Blum testified before the Committee that he was not aware that the Office of the Inspector General for the Department of Health and Human Services (OIG) and others had publicly stated that CMS does not have the legal authority to interfere in the negotiations between drug plans and pharma